Mode
Text Size
Log in / Sign up
N/A N=118

Using Tests in Preschool Children With Wheeze to Determine the Need for Inhaled Corticosteroid Therapy.

Wheezing

Enrolled (actual)
118
Serious AEs
0.0%
Results posted
Apr 2025
Primary outcome: Primary: Wheeze Attacks — 1 Wheeze attacks

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Blood eosinophil count (Diagnostic_test); Atopic sensitization (Diagnostic_test); FeNO (offline method) (Diagnostic_test)
Age
Pediatric · 1+ yrs
Sex
All
Sponsor
Imperial College London
Primary completion
Dec 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Wheeze Attacks
1
SECONDARY
Days Out of Nursery
3
SECONDARY
Parents Days Out of Work
3

Summary

Wheezing is common in preschool children and affects quality of life. Although asthma treatments such as inhaled steroids (ICS), which reduce swelling (inflammation) in the airways are used in this age group, they are often ineffective. That is because only some preschool children have the type of inflammation (known as Type 2 inflammation) that responds to ICS, thus many children are being unnecessarily exposed to side effects. It is difficult diagnosing Type 2 inflammation through history and examination, thus other indicators are needed to ensure ICS are only given to children who will benefit. These indicators are commonly known as biomarkers, and we are trying to find out if they are useful. We want to measure three biomarkers, without changing children's treatment. The first is blood eosinophils. which can be measured using a finger prick sample (like the blood drop used for measuring sugar levels in diabetic children). The second is to determine if allergic sensitization is present to allergens that are breathed in; these will be house dust mite, grass pollen, tree pollen, cat and dog hair. The final biomarker is a molecule that is produced in the airways of preschool children with Type 2 inflammation, called nitric oxide (NO). This is easily obtained, by having children breathe through a mask and collecting their breath in a bag, measuring NO later on. The children will be followed up with monthly electronic questionnaires and 3-monthly visits (virtual or face-to-face) for a year to evaluate whether these markers individually or in combination relate to subsequent wheezing outcomes, and how acceptable the measurements are to families using a questionnaire and focus group approach. The results will form the basis of the design of a national trial of biomarker-driven therapy in such children.

Eligibility Criteria

Inclusion Criteria

  • Patients aged one to five years old presenting to primary care or emergency department or urgent care centre or identified from primary care records and have been diagnosed with wheezing by their GP or paediatrician who has decided to prescribe any bronchodilator, ICS or montelukast on clinical grounds
  • Parents/Carers able to understand and familiarize themselves with the study and are willing to provide informed consent

Exclusion Criteria

  • Inability to understand and cooperate with study procedures
  • Significant co-morbidity (respiratory or otherwise), for example cystic fibrosis (excluding atopic disorders such as eczema, allergic rhinitis and food allergy)
  • Withholding or withdrawal of informed consent
  • Severe procedural anxiety (needle phobia)
  • Child is already enrolled in another study involving investigational medicinal product (CTIMP)
  • History of anaphylaxis or near-fatal asthma that resulted in intubation / assisted ventilation.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04942483). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search